Site-specific labeling of cytoplasmic peptide:N-glycanase by N,N'-diacetylchitobiose-related compounds.

Tadashi Suzuki, Izumi Hara, Miyako Nakano, Gang Zhao, William J Lennarz, Hermann Schindelin, Naoyuki Taniguchi, Kiichiro Totani, Ichiro Matsuo, Yukishige Ito

Journal: The Journal of biological chemistry 2006;281(31):22152-22160

PMID: 16740630

Abstract

Peptide:N-glycanase (PNGase) is the deglycosylating enzyme, which releases N-linked glycan chains from N-linked glycopeptides and glycoproteins. Recent studies have revealed that the cytoplasmic PNGase is involved in the degradation of misfolded/unassembled glycoproteins. This enzyme has a Cys, His, and Asp catalytic triad, which is required for its enzymatic activity and can be inhibited by "free" N-linked glycans. These observations prompted us to investigate the possible use of haloacetamidyl derivatives of N-glycans as potent inhibitors and labeling reagents of this enzyme. Using a cytoplasmic PNGase from budding yeast (Png1), Man9GlcNAc2-iodoacetoamide was shown to be a strong inhibitor of this enzyme. The inhibition was found to be through covalent binding of the carbohydrate to a single Cys residue on Png1, and the binding was highly selective. The mutant enzyme in which Cys191 of the catalytic triad was changed to Ala did not bind to the carbohydrate probe, suggesting that the catalytic Cys is the binding site for this compound. Precise determination of the carbohydrate attachment site by mass spectrometry clearly identified Cys191 as the site of covalent attachment. Molecular modeling of N,N'-diacetylchitobiose (chitobiose) binding to the protein suggests that the carbohydrate binding site is distinct from but adjacent to that of Z-VAD-fmk, a peptide-based inhibitor of this enzyme. These results suggest that cytoplasmic PNGase has a separate binding site for chitobiose and other carbohydrates, and haloacetamide derivatives can irreversibly inhibit that catalytic Cys in a highly specific manner.

Address: 21st Center of Excellence Program, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan. Electronic address: [email protected].; CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan.; 21st Center of Excellence Program, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.; Center for Structural Biology, Stony Brook University, Stony Brook, New York 11794-5215; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York 11794-5215.; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York 11794-5215.; Center for Structural Biology, Stony Brook University, Stony Brook, New York 11794-5215; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York 11794-5215; Rudolf Virchow Center for Experimental Biomedicine and Institute of Structural Biology, University of Würzburg, 97078 Würzburg, Germany.; 21st Center of Excellence Program, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; Department of Disease Glycomics, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.; CREST, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan; RIKEN, The Institute of Physical and Chemical Research, Wako 351-0198, Japan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.